Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biofrontera (BFRIW) Equity Average (2021 - 2025)

Historic Equity Average for Biofrontera (BFRIW) over the last 5 years, with Q3 2025 value amounting to -$3.6 million.

  • Biofrontera's Equity Average fell 14409.1% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year decrease of 14409.1%. This contributed to the annual value of $4.6 million for FY2024, which is 6782.11% down from last year.
  • Biofrontera's Equity Average amounted to -$3.6 million in Q3 2025, which was down 14409.1% from -$2.1 million recorded in Q2 2025.
  • Biofrontera's 5-year Equity Average high stood at $23.2 million for Q4 2022, and its period low was -$3.6 million during Q3 2025.
  • Over the past 5 years, Biofrontera's median Equity Average value was $3.9 million (recorded in 2023), while the average stood at $7.7 million.
  • Data for Biofrontera's Equity Average shows a peak YoY increase of 89181.38% (in 2025) and a maximum YoY decrease of 17585.08% (in 2025) over the last 5 years.
  • Over the past 5 years, Biofrontera's Equity Average (Quarter) stood at -$3.0 million in 2021, then skyrocketed by 869.17% to $23.2 million in 2022, then tumbled by 87.45% to $2.9 million in 2023, then soared by 70.86% to $5.0 million in 2024, then crashed by 172.76% to -$3.6 million in 2025.
  • Its last three reported values are -$3.6 million in Q3 2025, -$2.1 million for Q2 2025, and $2.5 million during Q1 2025.